The association between genetic polymorphism and risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.

激素消融疗法是治疗前列腺癌的标准疗法；然而，对治疗的反应持续时间存在很大的个体差异。在这项研究中，我们研究了甾体生成相关基因的遗传多态性变异与日本患者在雄激素剥夺治疗后发展为去势抵抗性前列腺癌（CRPC）的风险之间的关系。根据诊断后43个月（该队列中激素治疗的中位持续时间）进展为CRPC的病例对照状态分析不同基因型。在雄激素剥夺治疗中，CYP17A1基因多态性与进展为CPRC的风险相关，具有统计学意义。CYP17A1基因的遗传背景可能影响雄激素剥夺治疗后前列腺癌向CRPC的进展。

The hormone ablation therapy is the standard therapy for prostate cancer ; however, there is a large individual difference in the duration of response to the therapy. In this study, we have investigated the association between genetic polymorphic variations in steroidogenesis-related genes and risk of progression to Castration-Resistant Prostate Cancer(CRPC) in Japanese patients after androgen deprivation therapy.The different genotypes were analyzed according to case-control status of progression to CRPC at 43 months after diagnosis that is a median duration of hormonal therapy in this cohort.In the androgen deprivation therapy, the genetic polymorphisms in CYP17A1 are associated with a risk of progression to CPRC with statistic significance. The genetic backgrounds for CYP17A1 genes could influence the progression of prostate cancer to CRPC after androgen deprivation therapy.